NEW YORK (GenomeWeb News) – Hologic said on Thursday that Canadian regulators approved two of the company's assays for the detection of high-risk strains of human papillomavirus.

Health Canada granted medical device licenses to Hologic's Aptima HPV and Aptima HPV 16 18/45 genotype assays. Both assays are in vitro nucleic acid amplification tests for detecting HPV strains that are associated with cervical cancer and precancerous lesions, Hologic said. The assays were approved to run on the company's Tigris instrument.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers suggest that genetic variations could influence the side effects people experience when using synthetic cannabinoids, the International Business Times reports.

An analysis has examined the makeup of researchers on Twitter and what they share, Nature News reports.

At Stat News, Jim Kozubek argues that the Broad Institute is pushing the boundary of what a nonprofit is.

In PNAS this week: gut microbes may affect honeybee weight, phenotype and gene expression changes in DiGeorge syndrome, and more.